A Study of Pyridostigmine in Postural Tachycardia Syndrome
ConditionPostural Tachycardia Syndrome
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age15-55
SponsorMayo Clinic
About this trial
This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.
Eligibility criteria
Qualifiers
Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt.
Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking.
Disqualifiers
Pregnant or lactating women
Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study
Hypothyroidism or hyperthyroidism
Clinically significant coronary artery disease
Trial design
Treatments tested in this trial
- pyridostigmine
- Placebo
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Mayo Clinic
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator
Source ClinicalTrials.gov